AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28578654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study 26197801 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning approach (combination of face-to-face and online/mobile learning)
Number of subjects: 0
Study 26197801 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face method (ten 2-hour classes)
Number of subjects: 0
Study 23044732 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 37
Study 23044732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Training (IT)
Number of subjects: 37
Study 23044732 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 37
Study 23044732 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 37
Study 21309847 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised 10‐year CVD risk estimates
Number of subjects: 194
Study 21309847 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 194
Study 19816272 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating cutters
Number of subjects: 0
Study 19816272 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric terminals
Number of subjects: 0
Study 16890114 — intervention group
Group type: EXPERIMENTAL
Intervention: EC-MPS 1,080 mg twice daily
Number of subjects: 154
Study 16890114 — intervention group
Group type: COMPARATOR
Intervention: MMF 1,500 mg twice daily
Number of subjects: 154
Study 15292101 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 LNG rods (75 mg each) followed by 500 mg of TU by IM injection every 8 weeks for 24 weeks (Group I)
Number of subjects: 62
Study 15292101 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 LNG implants followed by 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group II)
Number of subjects: 62
Study 15292101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg of TU by IM injection every 8 weeks for 24 weeks (Group III)
Number of subjects: 62
Study 15292101 — intervention group
Group type: COMPARATOR
Intervention: Comparison of groups I, II, and III
Number of subjects: 62
Study 11308113 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer intervention for health promotion and risk reduction in pregnancy; 76 village women trained using low literacy techniques.
Number of subjects: 187
Study 11308113 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned; preintervention survey serves as baseline.
Number of subjects: 187
Study 9444444 — intervention group
Group type: COMPARATOR
Intervention: 5 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22
Study 9444444 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22
Study 9444444 — intervention group
Group type: COMPARATOR
Intervention: 15 mg of lubeluzole (1-hour intravenous infusion)
Number of subjects: 22
Study 9444444 — intervention group
Group type: COMPARATOR
Intervention: Lubeluzole (various doses)
Number of subjects: 22
Study 8197778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy followed by breast irradiation
Number of subjects: 0
Study 8197778 — intervention group
Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 0
Study 8197778 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy
Number of subjects: 0
Study 3884188 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐Ala2‐MePhe4‐met‐enkephalin‐O‐ol (DAMME)
Number of subjects: 2
Study 3884188 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 2
Study 3884188 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2
Study 29956042 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells (BM-MSC)
Number of subjects: 26
Study 29956042 — intervention group
Group type: COMPARATOR
Intervention: Optimum post-infarction treatment (Control group)
Number of subjects: 26
Study 24549094 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.2% NaCl/6% hydroxyethyl starch 200/0.5 (HSH)
Number of subjects: 40
Study 24549094 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl; control group)
Number of subjects: 40
Study 22219409 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with concomitant pulmonary vein isolation (PVI)
Number of subjects: 35
Study 22219409 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 35
Study 22219409 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with PVI
Number of subjects: 35
Study 20557578 — intervention group
Group type: EXPERIMENTAL
Intervention: São Pedro do Sul (SPS) thermal water
Number of subjects: 17
Study 20557578 — intervention group
Group type: COMPARATOR
Intervention: Purified water
Number of subjects: 17
Study 18599019 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac 0.4% plus prednisolone acetate 1% QID
Number of subjects: 546
Study 18599019 — intervention group
Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1% QID alone
Number of subjects: 546
Study 17726715 — intervention group
Group type: EXPERIMENTAL
Intervention: Designs with sample size reestimation
Number of subjects: 0
Study 17726715 — intervention group
Group type: COMPARATOR
Intervention: Fixed-size designs
Number of subjects: 0
Study 15003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fat (LF, 27%) group
Number of subjects: 63
Study 15003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified fat (MF, 37%E) group
Number of subjects: 63
Study 15003920 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (LF or MF)
Number of subjects: 63
Study 15003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat targets achievement
Number of subjects: 63
Study 15003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary contributions
Number of subjects: 63
Study 15003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuisine choices
Number of subjects: 63
Study 10699908 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) with repeated reinduction with PVDA
Number of subjects: 297
Study 10699908 — intervention group
Group type: COMPARATOR
Intervention: Weekly continuation chemotherapy with rotating pairs of drugs (teniposide and cytarabine, vincristine and cyclophosphamide) without repeated reinduction with PVDA
Number of subjects: 297
Study 10699908 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT) instead of continued chemotherapy
Number of subjects: 297
Study 9347435 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 0.3 mg/kg
Number of subjects: 60
Study 1485054 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 4033109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwoven microporous tape
Number of subjects: 0
Study 4033109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonwoven microporous reinforced tape
Number of subjects: 0
Study 4033109 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze tape
Number of subjects: 0
Study 4033109 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane tape
Number of subjects: 0
Study 30536967 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation time of 84 ms for real objects
Number of subjects: 0
Study 30536967 — intervention group
Group type: COMPARATOR
Intervention: Unlimited viewing time for real objects
Number of subjects: 0
Study 30536967 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation time of 84 ms for meaningless patterns
Number of subjects: 0
Study 30536967 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation time of 150 ms for meaningless patterns
Number of subjects: 0
Study 30536967 — intervention group
Group type: COMPARATOR
Intervention: Unlimited viewing time for meaningless patterns
Number of subjects: 0
Study 30536967 — intervention group
Group type: EXPERIMENTAL
Intervention: Presentation times of 84 ms and 150 ms for meaningless patterns
Number of subjects: 0
Study 29173822 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and home-based physical activity program (PAP) and simple lymphatic drainage (SLD), administered twice a week for six weeks.
Number of subjects: 52
Study 29173822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 52
Study 25493545 — intervention group
Group type: EXPERIMENTAL
Intervention: SBC (Salient Beliefs Condition)
Number of subjects: 116
Study 25493545 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (Planning Condition)
Number of subjects: 116
Study 25493545 — intervention group
Group type: EXPERIMENTAL
Intervention: CC (Combination Condition)
Number of subjects: 116
Study 25493545 — intervention group
Group type: COMPARATOR
Intervention: NSBC (Non-Salient Beliefs Condition)
Number of subjects: 116
Study 23297129 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide-prednisone
Number of subjects: 332
Study 23297129 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 332
Study 20229199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg disodium pamidronate, n=24)
Number of subjects: 39
Study 20229199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 39
Study 20229199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg disodium pamidronate)
Number of subjects: 39
Study 20229199 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate and Placebo
Number of subjects: 39
Study 19958945 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve monitoring of the EBSLN (group 1)
Number of subjects: 47
Study 19958945 — intervention group
Group type: COMPARATOR
Intervention: No nerve monitoring (group 2)
Number of subjects: 47
Study 16490472 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg BID
Number of subjects: 13274
Study 16490472 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg BID
Number of subjects: 13274
Study 16490472 — intervention group
Group type: COMPARATOR
Intervention: Nonselective NSAIDs (diclofenac 50 mg BID or naproxen 500 mg BID)
Number of subjects: 13274
Study 14988517 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg)
Number of subjects: 29
Study 14988517 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (50 mg)
Number of subjects: 29
Study 14988517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14988517 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Perilla frutescens enriched for rosmarinic acid (200 mg and 50 mg combined)
Number of subjects: 29
Study 10751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of heparin at 40- or 100-psi infusion pressure
Number of subjects: 57
Study 10751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of heparin at 100 psi
Number of subjects: 57
Study 10751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of heparin
Number of subjects: 57
Study 10751780 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 57
Study 9312717 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (IHT)
Number of subjects: 0
Study 9312717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study 8453959 — intervention group
Group type: EXPERIMENTAL
Intervention: New inhalation spacer device (Rondo) with salbutamol (Salbuvent)
Number of subjects: 15
Study 8453959 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (Ventoline) with Volumatic spacer
Number of subjects: 15
Study 8453959 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (Salbuvent) with conventional metered dose actuator
Number of subjects: 15
Study 8453959 — intervention group
Group type: EXPERIMENTAL
Intervention: New inhalation spacer device (Rondo)
Number of subjects: 15
Study 3518775 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (single dose, levels greater than 10 micrograms ml‐1)
Number of subjects: 0
Study 3518775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30035566 — intervention group
Group type: EXPERIMENTAL
Intervention: Doing everyday solitary activities (e.g., reading, watching TV)
Number of subjects: 2557
Study 30035566 — intervention group
Group type: COMPARATOR
Intervention: Thinking for pleasure
Number of subjects: 2557
Study 29067598 — intervention group
Group type: EXPERIMENTAL
Intervention: Religious Cognitive Behavioral Therapy (R-CBT)
Number of subjects: 79
Study 29067598 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Cognitive Behavioral Therapy (C-CBT)
Number of subjects: 79
Study 29067598 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 79
Study 28531392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasointestinal feeding
Number of subjects: 50
Study 28531392 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric feeding plus prokinetics (metoclopramide and erythromycin)
Number of subjects: 50
Study 25299079 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil preconditioning (R3 group, 1.8 μg·kg(‐1)·min(‐1))
Number of subjects: 40
Study 25299079 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil preconditioning (R3 group)
Number of subjects: 40
Study 25299079 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 40
Study 23097240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg b.i.d. for 6 days)
Number of subjects: 14
Study 23097240 — intervention group
Group type: COMPARATOR
Intervention: Safinamide (100 mg single dose)
Number of subjects: 14
Study 20403374 — intervention group
Group type: EXPERIMENTAL
Intervention: LiSM intervention (n=52)
Number of subjects: 101
Study 20403374 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control (n=49)
Number of subjects: 101
Study 18936500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20 mg three times daily, titrated to 40 mg and 80 mg as tolerated)
Number of subjects: 267
Study 18936500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 267
Study 18936500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study 15976803 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg daily
Number of subjects: 72
Study 15976803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 72
Study 15976803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 12073066 — intervention group
Group type: EXPERIMENTAL
Intervention: Double running suture (DRS)
Number of subjects: 68
Study 12073066 — intervention group
Group type: COMPARATOR
Intervention: Single running suture (SRS)
Number of subjects: 68
Study 9821026 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-patient treatment with low molecular weight heparin and oral anticoagulants, with daily attendance at the out-patient clinic.
Number of subjects: 523
Study 7644189 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol administration
Number of subjects: 71
Study 7644189 — intervention group
Group type: EXPERIMENTAL
Intervention: Head up tilt table test
Number of subjects: 71
Study 7644189 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for vasovagal syncope
Number of subjects: 71
Study 2504118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol cardioplegic solution (59.8 mmol/L)
Number of subjects: 40
Study 2504118 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioplegic solution
Number of subjects: 40
Study 2504118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol cardioplegic solution
Number of subjects: 40
Study 197443 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH4-10 (60 mg)
Number of subjects: 12
Study 197443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) minimization (n = 31)
Number of subjects: 69
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression (IS) free (n = 9)
Number of subjects: 69
Study 30229989 — intervention group
Group type: COMPARATOR
Intervention: Immunosuppression (IS) maintenance (n = 9)
Number of subjects: 69
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: IS minimization
Number of subjects: 69
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable IS monotherapy 1 year after transplantation
Number of subjects: 69
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute rejections
Number of subjects: 69
Study 30229989 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy-proven findings disqualifying patients from IS withdrawal
Number of subjects: 69
Study 28178149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of peripheral nerve block and general anesthesia (NB + GA)
Number of subjects: 120
Study 28178149 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (GA)
Number of subjects: 120
Study 25270758 — intervention group
Group type: EXPERIMENTAL
Intervention: WELLFOCUS PPT (11-week group positive psychology intervention)
Number of subjects: 37
Study 23364128 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-dependent self-knowledge intervention (We passages)
Number of subjects: 0
Study 23364128 — intervention group
Group type: COMPARATOR
Intervention: Independent self-knowledge intervention (I passages)
Number of subjects: 0
Study 21771098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT) applied twice daily for 4 weeks
Number of subjects: 0
Study 21771098 — intervention group
Group type: COMPARATOR
Intervention: Pimecrolimus 1% cream (PIM)
Number of subjects: 0
Study 21771098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT)
Number of subjects: 0
Study 21771098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 1% cream (HCT) and Pimecrolimus 1% cream (PIM)
Number of subjects: 0
Study 19337726 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant (20 mg)
Number of subjects: 30
Study 19337726 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 30
Study 16816943 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.02 mg/kg body weight)
Number of subjects: 20
Study 16816943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15488446 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load with ego threat (CNS task)
Number of subjects: 119
Study 15488446 — intervention group
Group type: COMPARATOR
Intervention: Low cognitive load with processing and memorisation of colour nouns (CNS task)
Number of subjects: 119
Study 15488446 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load (CNS task)
Number of subjects: 119
Study 10943739 — intervention group
Group type: EXPERIMENTAL
Intervention: GH‐1 gene deletion screening using PCR method
Number of subjects: 48
Study 10943739 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sequencing analysis
Number of subjects: 48
Study 10102659 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (n=16)
Number of subjects: 49
Study 10102659 — intervention group
Group type: COMPARATOR
Intervention: Standard term formula (F) (n=15)
Number of subjects: 49
Study 10102659 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with egg yolk lecithin providing DHA (0.15%) and AA (0.30%) (LCP-F) (n=18)
Number of subjects: 49
Study 7919671 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg/L) and heparin (500 U/L) added to peripheral intravenous fluid (feed A)
Number of subjects: 0
Study 7919671 — intervention group
Group type: COMPARATOR
Intervention: Peripheral intravenous fluid without heparin and hydrocortisone (feed B)
Number of subjects: 0
Study 2904523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (15 ng/kg/min)
Number of subjects: 10
Study 2904523 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (30 ng/kg/min)
Number of subjects: 10
Study 2904523 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose solution (5.4 ml/h)
Number of subjects: 10
Study 31323771 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch at a restaurant/take-out (n = 84, 4%)
Number of subjects: 2075
Study 31323771 — intervention group
Group type: COMPARATOR
Intervention: Post-policy food outlet access within 1000 m of schools
Number of subjects: 2075
Study 31323771 — intervention group
Group type: COMPARATOR
Intervention: Overall food outlet numbers over time
Number of subjects: 2075
Study 29305401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss diet intervention (low-calorie diet)
Number of subjects: 510
Study 26956188 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.5 pmol·kg–1·min–1)
Number of subjects: 0
Study 26956188 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 24271347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-phone support with study funded phone plans
Number of subjects: 37
Study 21599819 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg bid with tenofovir/emtricitabine
Number of subjects: 1262
Study 21599819 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg bid with optimized background therapy
Number of subjects: 1262
Study 21599819 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg at bedtime with tenofovir/emtricitabine
Number of subjects: 1262
Study 21599819 — intervention group
Group type: COMPARATOR
Intervention: Placebo with optimized background therapy
Number of subjects: 1262
Study 21599819 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 1262
Study 19067473 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 90 mg
Number of subjects: 0
Study 19067473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17991641 — intervention group
Group type: COMPARATOR
Intervention: Low-fat (LF) diet providing 30.8% of energy from fat and 5.2% from polyunsaturated fat (PUFA)
Number of subjects: 24
Study 17991641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet providing 37.9% of energy from fat and 5.8% from PUFA
Number of subjects: 24